Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $204.67

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $204.67.

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. UBS Group began coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price for the company. Evercore ISI upped their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock traded down $0.57 on Friday, reaching $157.57. The company had a trading volume of 118,975 shares, compared to its average volume of 485,742. The firm has a market cap of $9.61 billion, a price-to-earnings ratio of -22.19 and a beta of 0.54. The firm's 50-day moving average price is $153.31 and its two-hundred day moving average price is $138.53. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently modified their holdings of ASND. Diversified Trust Co raised its holdings in Ascendis Pharma A/S by 3.4% in the first quarter. Diversified Trust Co now owns 46,548 shares of the biotechnology company's stock worth $7,255,000 after purchasing an additional 1,510 shares during the period. Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S during the first quarter worth about $226,000. Harbor Capital Advisors Inc. raised its holdings in Ascendis Pharma A/S by 1.3% during the first quarter. Harbor Capital Advisors Inc. now owns 85,960 shares of the biotechnology company's stock worth $13,398,000 after acquiring an additional 1,087 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in Ascendis Pharma A/S in the first quarter valued at approximately $832,000. Finally, GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 15,593.0% in the first quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company's stock valued at $142,600,000 after buying an additional 90,907 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.